Published in Ann Surg Oncol on November 10, 2006
Intraperitoneal therapy for peritoneal cancer. Future Oncol (2010) 1.25
Pseudomyxoma peritonei: a need to establish evidence-based standard of care--is this the right trial? Ann Surg Oncol (2009) 0.95
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer (2014) 0.90
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer: 2-year follow-up results at a single institution in Korea. Ann Surg Treat Res (2016) 0.89
Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. World J Gastrointest Oncol (2011) 0.88
Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy. Clin Colon Rectal Surg (2015) 0.82
Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal carcinoma: preliminary results. ISRN Surg (2011) 0.81
Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. Surg Today (2014) 0.79
Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol (2015) 0.78
Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview. World J Gastrointest Oncol (2014) 0.77
Laparoscopic cytoreductive surgery and early postoperative intraperitoneal chemotherapy for patients with colorectal cancer peritoneal carcinomatosis: initial results from a single center. Surg Endosc (2013) 0.76
An evolving role of perioperative intraperitoneal chemotherapy after cytoreductive surgery for colorectal peritoneal carcinomatosis. Ann Surg Oncol (2007) 0.76
Surgical treatment of peritoneal carcinomatosis: current treatment modalities. Langenbecks Arch Surg (2013) 0.76
Incidence of leukopenia after intraperitoneal vs combined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei. World J Gastrointest Pharmacol Ther (2016) 0.75
Surgery for Colorectal Cancer - Trends, Developments, and Future Perspectives. Visc Med (2016) 0.75
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy. Indian J Surg Oncol (2016) 0.75
Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis. World J Gastroenterol (2009) 0.75
A case report of surgical resections with local and systemic chemotherapy for three recurrences of colon cancer occurring ten years after colectomy. Case Rep Oncol (2012) 0.75
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget (2017) 0.75
HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J (2003) 6.44
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol (2011) 2.26
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol (2005) 1.96
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer (2007) 1.86
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol (2010) 1.74
Use of intensive care in patients with nonresectable lung cancer. Chest (2010) 1.71
Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol (2007) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery (2005) 1.51
Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology (2010) 1.51
Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. Gastroenterol Clin Biol (2007) 1.48
Adult duct-lining cells can reprogram into β-like cells able to counter repeated cycles of toxin-induced diabetes. Dev Cell (2013) 1.46
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology (2006) 1.45
Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol (2005) 1.40
Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg (2008) 1.32
Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer (2013) 1.31
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol (2005) 1.27
Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology (2005) 1.26
The role of clips in preventing migration of fully covered metallic esophageal stents: a pilot comparative study. Surg Endosc (2011) 1.26
HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol (2004) 1.22
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol (2007) 1.21
Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg (2013) 1.19
Pancreatic metastases: a multicentric study of 22 patients. Gastroenterol Clin Biol (2004) 1.18
Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging (2007) 1.08
Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol (2005) 1.07
CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet (2013) 1.05
Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. J Vasc Interv Radiol (2010) 1.03
Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer (2014) 1.03
Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg (2010) 1.03
Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol (2007) 1.02
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer (2009) 1.01
Peritoneal carcinomatosis of colorectal origin. Gastroenterol Clin Biol (2006) 1.01
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res (2011) 1.00
Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. Gastroenterol Clin Biol (2006) 0.99
Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol (2011) 0.98
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol (2007) 0.96
Treatment of advanced pancreatic cancer. Semin Oncol (2007) 0.95
Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. Oncology (2012) 0.91
Preoperative criteria of incomplete resectability of peritoneal carcinomatosis from non-appendiceal colorectal carcinoma. Gastroenterol Clin Biol (2005) 0.90
Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist (2012) 0.90
Nutritional risk factors in planned oncologic surgery: what clinical and biological parameters should be routinely used? World J Surg (2009) 0.90
Green urine after intragastric balloon placement for the treatment of morbid obesity. Obes Surg (2003) 0.89
Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. J Immunol Methods (2008) 0.89
Thyroid metastases from colorectal cancer: the Institut Gustave Roussy experience. Eur J Cancer (2006) 0.89
Antiangiogenic agents and late anastomotic complications. J Surg Oncol (2010) 0.88
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer (2006) 0.87
Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy. J Surg Oncol (2005) 0.87
Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study. Ann Surg (2012) 0.86
The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome. Ann Surg Oncol (2009) 0.86
Benefits of contrast-enhanced sonography for the detection of liver lesions: comparison with histologic findings. AJR Am J Roentgenol (2008) 0.86
Flexible fiberoptic bronchoscopy and remifentanil target-controlled infusion in ICU: a preliminary study. Intensive Care Med (2012) 0.86
Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg (2014) 0.85
Sentinel lymph node sampling and analysis in colon cancer: what is the question? J Clin Oncol (2006) 0.84
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis. Ann Surg Oncol (2012) 0.84
Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol (2011) 0.83
Balance between pro and anti-inflammatory cytokines in patients with acute alcoholic hepatitis. Gastroenterol Clin Biol (2005) 0.82
[Standards, Options and Recommendations 2005 for a good practice in enteral nutrition in oncology (summary report.)]. Bull Cancer (2006) 0.82
Intrathecal + PCA morphine improves analgesia during the first 24 hr after major abdominal surgery compared to PCA alone. Can J Anaesth (2003) 0.82
Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol (2014) 0.81
Indwelling time and risk of infection of dialysis catheters in critically ill cancer patients. Intensive Care Med (2005) 0.81
Serum leptin in patients with alcoholic liver disease. Alcohol Clin Exp Res (2006) 0.80
Antitumoral effect of celecoxib in hepatocellular carcinoma. J Clin Oncol (2005) 0.80
Cleft lip, cleft palate, hereditary diffuse gastric cancer and germline mutations in CDH1. Int J Cancer (2012) 0.79
[Colorectal cancer: prognostic molecular markers]. Gastroenterol Clin Biol (2004) 0.79
Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study. World J Surg (2005) 0.78
The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure. Best Pract Res Clin Gastroenterol (2007) 0.78
The trans-metastasis hepatectomy (through metastases previously ablated with radiofrequency): results of a 13-case study of colorectal cancer. J Surg Oncol (2006) 0.78
Diversity of the clinical presentation of the MMR gene biallelic mutations. Fam Cancer (2014) 0.78
Simultaneous decompression colonoscopy and radiologic G-tube insertion in a patient with megacolon because of chronic colonic pseudo-obstruction. Gastrointest Endosc (2005) 0.78
[Can children visit their relatives in an adult ICU?]. Bull Cancer (2007) 0.78
A simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. Ann Surg Oncol (2014) 0.77
CA 19-9 and pancreatic carcinoma, a revival? Onkologie (2007) 0.77
The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Support Care Cancer (2009) 0.77
Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol (2005) 0.77
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs (2014) 0.77
[Therapeutic strategies using VEGF inhibitors in colorectal cancer]. Bull Cancer (2005) 0.76
Biliary cancers, chemotherapy, and cetuximab. Lancet Oncol (2010) 0.75
Emerging drugs in pancreatic cancer. Expert Opin Emerg Drugs (2004) 0.75
[Malnutrition in cancer patients]. Rev Prat (2006) 0.75
An Unusual Case of Constitutional Mismatch Repair Deficiency Syndrome With Anaplastic Ganglioglioma, Colonic Adenocarcinoma, Osteosarcoma, Acute Myeloid Leukemia, and Signs of Neurofibromatosis Type 1: Case Report. Neurosurgery (2015) 0.75
Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment. J Clin Oncol (2007) 0.75
[Colorectal cancer in France: towards an improvement in therapy?]. Gastroenterol Clin Biol (2004) 0.75
[Renal, hepatic, biliary, and cardiovascular emergencies in onco-haematology]. Rev Prat (2003) 0.75
[How can we integrate nutritional support in medical oncology?]. Bull Cancer (2009) 0.75
[What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]. Gastroenterol Clin Biol (2006) 0.75
[Chronic TVT infection: mechanisms and consequences]. Prog Urol (2004) 0.75
Gallbladder carcinoma secondary to repetitive hepatic arterial chemoembolization. Am J Gastroenterol (2002) 0.75
[Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view]. Bull Cancer (2008) 0.75